Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
出版年份 2017 全文链接
标题
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
作者
关键词
FDG PET, PERCIST, EORTC criteria, Oncology, Treatment monitoring
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 44, Issue S1, Pages 55-66
出版商
Springer Nature
发表日期
2017-03-30
DOI
10.1007/s00259-017-3687-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Precision medicine needs randomized clinical trials
- (2017) Everardo D. Saad et al. Nature Reviews Clinical Oncology
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
- (2016) Bruce D. Cheson et al. BLOOD
- Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
- (2016) Matjaz Zwitter et al. CANCER BIOLOGY & THERAPY
- Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver
- (2016) Faramarz Edalat et al. CLINICAL NUCLEAR MEDICINE
- Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer
- (2016) Jingjie Shang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib
- (2016) Kung-Chu Ho et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival
- (2016) Vadim S. Koshkin et al. JOURNAL OF CLINICAL ONCOLOGY
- The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST
- (2016) K. Pinker et al. JOURNAL OF NUCLEAR MEDICINE
- Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment
- (2016) G. J. R. Cook et al. JOURNAL OF NUCLEAR MEDICINE
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer
- (2016) Giuseppe Luigi Banna et al. ONCOLOGY
- Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition
- (2016) Gerald S. M. A. Kerner et al. PLoS One
- Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0
- (2016) Joo Hyun O et al. RADIOLOGY
- Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review
- (2016) Jung Han Kim Oncotarget
- Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
- (2016) Seon Jeong Min et al. Oncotarget
- Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy
- (2016) Joan Fledelius et al. EJNMMI Research
- Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
- (2016) Kristine R. Broglio et al. JAMA Oncology
- Comparison of Metabolic and Anatomic Response to Chemotherapy Based on PERCIST and RECIST in Patients with Advanced Stage Non-small Cell Lung Cancer
- (2015) Cetin Ordu et al. Asian Pacific Journal of Cancer Prevention
- Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome
- (2015) Jose G. Monzon et al. EUROPEAN JOURNAL OF CANCER
- Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods
- (2015) Ming-Wen An et al. JOURNAL OF CLINICAL ONCOLOGY
- PET Response Criteria in Solid Tumors Predicts Progression-Free Survival and Time to Local or Distant Progression After Chemotherapy with Regional Hyperthermia for Soft-Tissue Sarcoma
- (2015) W. P. Fendler et al. JOURNAL OF NUCLEAR MEDICINE
- Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials
- (2015) W. A. Weber et al. JOURNAL OF NUCLEAR MEDICINE
- Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
- (2015) Ming-Wen An et al. JNCI-Journal of the National Cancer Institute
- Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial
- (2015) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Response assessment criteria for brain metastases: proposal from the RANO group
- (2015) Nancy U Lin et al. LANCET ONCOLOGY
- Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors
- (2015) Mustafa Aras et al. NUCLEAR MEDICINE COMMUNICATIONS
- Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?
- (2015) Merdan Fayda et al. TUMOR BIOLOGY
- Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
- (2015) Ming-Wen An et al. JNCI-Journal of the National Cancer Institute
- Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings
- (2015) Eduardo Bruno Lobato Martins et al. PLoS One
- Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test-Retest Measurements for Tumor FDG Uptake, Diameter, and Volume
- (2014) A. G. Rockall et al. CLINICAL CANCER RESEARCH
- PET Response Criteria for Solid Tumors Predict Survival at Three Months After Intra-Arterial Resin-Based 90Yttrium Radioembolization Therapy for Unresectable Intrahepatic Cholangiocarcinoma
- (2014) Juan C. Camacho et al. CLINICAL NUCLEAR MEDICINE
- Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?
- (2014) Laurent Dercle et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- SDHBmutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
- (2014) Julien Hadoux et al. INTERNATIONAL JOURNAL OF CANCER
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
- (2014) Bruno Coudert et al. LANCET ONCOLOGY
- Early detection of disease progression after palliative chemotherapy in NSCLC patients by 18F-FDG-PET
- (2014) E. Tauhardt et al. NUKLEARMEDIZIN-NUCLEAR MEDICINE
- Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment
- (2014) Mi Na Kim et al. Expert Review of Gastroenterology & Hepatology
- CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
- (2014) Kristin Skougaard et al. Cancer Medicine
- Phase I Trial of Selective Internal Radiation Therapy for Chemorefractory Colorectal Cancer Liver Metastases Progressing After Hepatic Arterial Pump and Systemic Chemotherapy
- (2013) Constantinos T. Sofocleous et al. Clinical Colorectal Cancer
- Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab
- (2013) K. Skougaard et al. JOURNAL OF NUCLEAR MEDICINE
- Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
- (2013) D. Ziai et al. CANCER IMAGING
- Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors
- (2012) M. Yanagawa et al. JOURNAL OF NUCLEAR MEDICINE
- Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis
- (2012) A. J. de Langen et al. JOURNAL OF NUCLEAR MEDICINE
- Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer
- (2012) H. K. Gan et al. JNCI-Journal of the National Cancer Institute
- Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging—Prospective Assessment
- (2012) Ukihide Tateishi et al. RADIOLOGY
- 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
- (2012) Curtis A. Thacker et al. Cancer Medicine
- Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer
- (2010) Patrick G. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers and surrogate end points—the challenge of statistical validation
- (2010) Marc Buyse et al. Nature Reviews Clinical Oncology
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine
- (2009) Tudor E. Ciuleanu et al. EUROPEAN JOURNAL OF CANCER
- [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
- (2009) Wen Wee Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies
- (2009) L. M. Velasquez et al. JOURNAL OF NUCLEAR MEDICINE
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma
- (2008) L. H. Wei et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started